Q3 2025 FINANCIAL RESULTS (GlobeNewswire) - Oct 30, 2025 - "Recognized $1.4 million in grant revenue in the third quarter of 2025 compared to $1.5 million in the same quarter of 2024, which represents CPRIT's share of the costs incurred for our REYOBIQ platform advancement for the treatment of patients with LM."
Commercial • Brain Cancer • CNS Tumor
|